-The Economic Times Six years after Prime Minister Manmohan Singh first urged India Inc to pro-actively offer employment to the less privileged sections of society, the government has not been able to walk the talk. A special recruitment drive initiated by it has failed to meet targets. Under the government's affirmative drive launched in 2008 and focused purely on offering jobs to candidates from Scheduled Castes, Scheduled Tribes, Other Backward Classes...

-The Hindu The Justice Verma Committee report acts as a blueprint for the radical transformation of gender relations within the framework of constitutional guarantees and gender equality. However, the adoption of the Criminal Law Amendment Act 2013 by Parliament on March 19, 2013, does not go beyond legal change. Prof. Hasan argues that if political parties are serious about the rights of women, the Women's Representation Bill must be passed...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...

-Tehelka A public issue is not truly public unless Markandey Katju has passed judgement. Rahul Kotiyal and Ajachi Chakrabarti stand downwind "Journalists" writes Markandey Katju, with little sense of irony, "comment on everything under the sun." He goes on to say that when the shoe is on the other foot, when someone comments on journalism, it is misconstrued as an attack on press freedom. That when he announces he is appointing a...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...